ASCO: Antibody Boosts Chemo in CLL MedPage Today CHICAGO -- Adding the novel anti-CD20 agent obinutuzumab to standard chemotherapy for older, sicker patients with chronic lymphocytic leukemia improves outcomes, possibly more so than adding rituximab (Rituxan), the pivotal CLL11 trial showed. |
